Keyphrases
Exendin-4 (Ex-4)
100%
Dual Agonist
100%
Gastrin
100%
Antidiabetic Effect
100%
Zucker Rats
100%
Glucagon-like peptide-1 (GLP-1)
100%
B Cells
60%
Glycemic Control
60%
Gastrin-17 (G-17)
60%
Combination Treatment
40%
Glucose Tolerance
40%
Cell Fraction
40%
β-cell Dysfunction
40%
Oral Glucose Tolerance Test
40%
Therapeutic Potential
20%
Diabetic
20%
Do-All
20%
Diabetic Mice
20%
Level Tolerance
20%
Type 2 Diabetes Mellitus (T2DM)
20%
Diabetes Management
20%
Morphometric Analysis
20%
Liraglutide
20%
Insulin Level
20%
β-cell Mass
20%
HbA1c Levels
20%
Control Cell
20%
Vehicle Groups
20%
High Dose
20%
Monotherapy
20%
Alpha Cell
20%
Chronic Effects
20%
Hemoglobin A1c (HbA1c)
20%
Blood Glucose
20%
Cell Dynamics
20%
Medicine and Dentistry
Gastrin
100%
Glucagon Like Peptide 1
100%
Exenatide
100%
Antidiabetic Activity
100%
Beta Cell
100%
Glycemic Control
60%
Gastrin 17
60%
Hemoglobin A1c
40%
Glucose Tolerance
40%
Oral Glucose Tolerance Test
40%
Maturity Onset Diabetes of the Young
20%
Drug Megadose
20%
Monotherapy
20%
Liraglutide
20%
Diabetes Mellitus
20%
Blood Glucose
20%
Morphometric Analysis
20%
Diabetes
20%
Pharmacology, Toxicology and Pharmaceutical Science
Zucker Diabetic Fatty Rat
100%
Antidiabetic Agent
100%
Gastrin
100%
Glucagon-Like Peptide-1
100%
Exendin 4
100%
Gastrin 17
60%
Hemoglobin A1c
40%
Liraglutide
20%
Non Insulin Dependent Diabetes Mellitus
20%
Monotherapy
20%
Diabetes Mellitus
20%